[
  {
    "ts": null,
    "headline": "States sue to block sale of 23andMe’s personal genetic data without customer consent",
    "summary": "States sue to block sale of 23andMe’s personal genetic data without customer consent",
    "url": "https://finnhub.io/api/news?id=456c642d6c1bae1d94c46a79d96b28fbd94486bc54221ed7d353ad069c34c5e0",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749512100,
      "headline": "States sue to block sale of 23andMe’s personal genetic data without customer consent",
      "id": 135159707,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "States sue to block sale of 23andMe’s personal genetic data without customer consent",
      "url": "https://finnhub.io/api/news?id=456c642d6c1bae1d94c46a79d96b28fbd94486bc54221ed7d353ad069c34c5e0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
    "url": "https://finnhub.io/api/news?id=467b470f903df0db34aac6c15f334d20b046f0dbefccd5ce3d19dd4db04ce6a3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749486600,
      "headline": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "id": 135159708,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day",
      "url": "https://finnhub.io/api/news?id=467b470f903df0db34aac6c15f334d20b046f0dbefccd5ce3d19dd4db04ce6a3"
    }
  },
  {
    "ts": null,
    "headline": "Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season",
    "summary": "French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November and runs through March. Sanofi, in collaboration with its partner AstraZeneca plc (NASDAQ:AZN), has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023. Immunizations begin in early fall. The",
    "url": "https://finnhub.io/api/news?id=73b3ff35c7310bb4a3c9ebea20894954ac5579a9793c6a60dc0640cfbe92e930",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749481229,
      "headline": "Beyfortus Output Tripled As Sanofi, AstraZeneca Scale Up For RSV Season",
      "id": 135131329,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "French drugmaker Sanofi SA (NASDAQ:SNY) on Monday said it is shipping Beyfortus (nirsevimab) starting in early Q3 to ensure broad availability well ahead of the 2025-2026 respiratory syncytial virus (RSV) season, which typically starts in November and runs through March. Sanofi, in collaboration with its partner AstraZeneca plc (NASDAQ:AZN), has tripled production capacity and doubled the number of manufacturing sites since the launch of Beyfortus in 2023. Immunizations begin in early fall. The",
      "url": "https://finnhub.io/api/news?id=73b3ff35c7310bb4a3c9ebea20894954ac5579a9793c6a60dc0640cfbe92e930"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron and Sanofi’s dupilumab shows promise in AD trial",
    "summary": "In the study, 120 subjects with AD and skin of colour received Dupixent biweekly.",
    "url": "https://finnhub.io/api/news?id=25dc0f43035cf0d5d8e9ea5ef4f49a5312f92e71c7fa9b5d39cf11134bf730e0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749479406,
      "headline": "Regeneron and Sanofi’s dupilumab shows promise in AD trial",
      "id": 135127955,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "In the study, 120 subjects with AD and skin of colour received Dupixent biweekly.",
      "url": "https://finnhub.io/api/news?id=25dc0f43035cf0d5d8e9ea5ef4f49a5312f92e71c7fa9b5d39cf11134bf730e0"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ParticipantsChristopher...",
    "url": "https://finnhub.io/api/news?id=1e9eb4b745be36d1cd8b9fd024cda8e7c0f6c9f101f9f757333a678d93099195",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749473055,
      "headline": "Regeneron Pharmaceuticals, Inc. (REGN) Presents at 46th Annual Goldman Sachs Global Healthcare Conference Transcript",
      "id": 135136647,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) 46th Annual Goldman Sachs Global Healthcare Conference June 9, 2025 10:40 AM ETCompany ParticipantsChristopher...",
      "url": "https://finnhub.io/api/news?id=1e9eb4b745be36d1cd8b9fd024cda8e7c0f6c9f101f9f757333a678d93099195"
    }
  },
  {
    "ts": null,
    "headline": "Transcript : Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10",
    "summary": "Presenter SpeechSalveen Richter Good morning, everyone. Thank you for joining us, I am Salveen Richter biotechnology analyst at Goldman Sachs and really pleased to be joined by the Regeneron team....",
    "url": "https://finnhub.io/api/news?id=fdd75ab1e198fa48d528ce15ad91be00e708fd510879f8dc3f19337e1de3f0c6",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749472525,
      "headline": "Transcript : Regeneron Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 10",
      "id": 135136556,
      "image": "",
      "related": "REGN",
      "source": "Finnhub",
      "summary": "Presenter SpeechSalveen Richter Good morning, everyone. Thank you for joining us, I am Salveen Richter biotechnology analyst at Goldman Sachs and really pleased to be joined by the Regeneron team....",
      "url": "https://finnhub.io/api/news?id=fdd75ab1e198fa48d528ce15ad91be00e708fd510879f8dc3f19337e1de3f0c6"
    }
  },
  {
    "ts": null,
    "headline": "As tech leads, which stocks have outperformed since April 8 rout?",
    "summary": "Tech is back in the driver’s seat, with the sector reigniting the flames across the market indexes (^DJI, ^IXIC, ^GSPC) since their April 8 lows on the rollout of President Trump's \"Liberation Day\" tariffs. Yahoo Finance markets and data editor Jared Blikre — who also hosts the Stocks In Translation podcast — breaks down the top gainers, from Nvidia's (NVDA) $1 trillion surge to surprise winners like Oracle (ORCL) and Seagate Technology (STX), to some of the biggest losers in that period. Twice a week, Stocks In Translation cuts through the market mayhem, noisy numbers and hyperbole to give you the information you need to make the right trade for your portfolio. You can find more episodes here, or watch on your favorite streaming service. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
    "url": "https://finnhub.io/api/news?id=677a027bb624b9b41b53692a94d075b6623f3601cc81b1ec4a4eb96d95805ef9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749463205,
      "headline": "As tech leads, which stocks have outperformed since April 8 rout?",
      "id": 135123077,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Tech is back in the driver’s seat, with the sector reigniting the flames across the market indexes (^DJI, ^IXIC, ^GSPC) since their April 8 lows on the rollout of President Trump's \"Liberation Day\" tariffs. Yahoo Finance markets and data editor Jared Blikre — who also hosts the Stocks In Translation podcast — breaks down the top gainers, from Nvidia's (NVDA) $1 trillion surge to surprise winners like Oracle (ORCL) and Seagate Technology (STX), to some of the biggest losers in that period. Twice a week, Stocks In Translation cuts through the market mayhem, noisy numbers and hyperbole to give you the information you need to make the right trade for your portfolio. You can find more episodes here, or watch on your favorite streaming service. To watch more expert insights and analysis on the latest market action, check out more Catalysts here.",
      "url": "https://finnhub.io/api/news?id=677a027bb624b9b41b53692a94d075b6623f3601cc81b1ec4a4eb96d95805ef9"
    }
  },
  {
    "ts": null,
    "headline": "Alcon's Tryptyr Adds Growth, But Valuation Keeps Shares On 'Hold'",
    "summary": "Alcon posts steady growth in Vision Care and Surgical, with new drug and therapy launches ahead but execution risks persist. Read why ALC stock is a hold.",
    "url": "https://finnhub.io/api/news?id=6b1edd9ac6b49e70210fa65c0b5cc85c23e3db6dd2c08d2e413e847ac148f02a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1749454200,
      "headline": "Alcon's Tryptyr Adds Growth, But Valuation Keeps Shares On 'Hold'",
      "id": 135122867,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/951515174/image_951515174.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Alcon posts steady growth in Vision Care and Surgical, with new drug and therapy launches ahead but execution risks persist. Read why ALC stock is a hold.",
      "url": "https://finnhub.io/api/news?id=6b1edd9ac6b49e70210fa65c0b5cc85c23e3db6dd2c08d2e413e847ac148f02a"
    }
  }
]